House passes AHA-supported bills to promote generic drug competition
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year. The…
Headline
AHA and the Institute for Diversity and Health Equity released the fifth and final installment in its five-part DEI Data Insights series, which highlights…
Headline
The AHA July 15 commented to Sens. Sheldon Whitehouse, D-R.I., and Bill Cassidy, R-La., responding to a request for information based on the Pay PCPs Act,…
Chairperson's File
We know that health equity matters. But what exactly does the term mean? AHA’s Institute for Diversity and Health Equity defines “health equity” as “The fair…
Headline
Evan Williams, a certified association executive, will serve as new executive director for the American Society for Health Care Risk Management and the Society…
Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…